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Introduction 
In recent studies, it has been seen that cancer cell detection 
in the initial stage and its treatment are getting complex 
with passing days. Treatment of various cancers and 
psychosis gets problematic if the initial stage detection is 
not made on time1-4. Apart from this, sometimes drug 
delivery at specific cancer affected area become impossible 
for some specific characteristic feature of the functioning of 
the chemotherapeutic drugs. To address the issue, the use 
of nanoparticles, anti-MiRs, exosomes, and DNA 
modification is seeing a high. Along with it, histone 
modification is getting used to addressing this problem5-11.  
Numerous ways are followed to address the issues relating 
to cancer treatment, and psychosis. Detection, 
management, and treatment of brain tumor-like 
glioblastoma are getting tougher with passing years. 
Chemotherapy is not only usually used into the treatment 
of a brain tumor, but also it has some drawbacks like an 
increase in the level of cytotoxicity and drug resistance12-23. 
To meet with the issue use of specially designed 
nanoparticles with chemotherapeutic drugs are increasing. 
Similarly, to control the problems like multidrug resistance 
the use of nanoparticles with the capability of co-delivery of 
dual drugs has been started. Multidrug resistance (MDR) 
mainly impacts the treatment of malignant cells of the 
human body24-29.  
To minimize the challenges concerned with the 
conventional way of drug delivery, this new process of drug 
delivery process has been invented.    
Hence, to minimize the issues like toxicity and deaths due 
to a higher dosage of chemotherapeutic drugs 
nanoparticles with the capability of co-delivery of dual 
drugs into the affected areas of the human body30-35. 
Sometimes, the single and combined drug delivery becomes 
necessary for saving the normal tissues from getting 
destroyed. Nano-sized Camptothecin is used these days for 
this kind of individual and combined drug delivery at the 
affected areas36-40.  
The antipsychotic drugs used in these days sometimes 
cause several fatal side effects in the human body. 
Metabolic syndromes and sometimes movement disorder 
are those fatal outcomes caused by those imperfect 
antipsychotic drugs41-44. Nanoparticles of the size between 
1-500nm are mainly used with the antipsychotic drugs to 
address the issue. It helps the drug to pass through the 
blood-brain barriers so that it can work properly and those 
side effects can get solved45.  
Nanoparticle introduction into the chemotherapeutic drug 
not only helps to minimize the impact like cytotoxicity and 
drug resistance but also assists the chemotherapeutic drugs 
to become capable of passing through the blood-brain 
barrier. Without the incorporation of nanoparticles with 
the drug, it is impossible to make the chemotherapeutic 
drug passable through the blood-brain barrier46-49. To meet 
with the issues of drug resistance the use of high dose 
chemotherapeutic drugs gets preferred sometimes, but it 
causes a high level of intoxication and even death of the 
patient. Nanoparticles that are used combined with 
chemotherapeutic drugs mainly enhances the permeability 
of the cellular membrane of the human body through which 
the drugs get incorporated into the affected area of the 
human body. Nanoparticles not only allow the drugs to pass 
through the blood vessels but also help to retain the 
medications for a more extended period so that it can work 
properly50,51.
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Figure 1: Core-matched nano-emulsions co-delivering PTX and 5-FU13.  
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